RecruitingEarly Phase 1

Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis

China9 participantsStarted 2018-09-17

Plain-language summary

Treatment for Calciphylaxis Patients with Human Amniotic-derived Mesenchymal Stem Cells

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. 18-75 years old.
✓. Clinical diagnosis of calciphylaxis, including patients with chronic kidney disease who did not or had regular dialysis (hemodialysis or peritoneal dialysis).
✓. All subjects signed informed consent.

✕. Patients who refuse to sign informed consent.
✕. Patients with malignant tumors or severe psychiatric disorders, or an expected survival time of less than 6 months.
✕. Pregnant or lactating women of childbearing age.
✕. Participation in another clinical trial with an experimental drug within 90 days prior the inclusion.

Wound Healing

Timeframe: Up to 1 year.

NCT IDNCT04592640

SponsorThe First Affiliated Hospital with Nanjing Medical University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-09-17

Ningning Wang, Professor